IQVIA (NYSE:IQV) Now Covered by Analysts at BTIG Research

Equities research analysts at BTIG Research assumed coverage on shares of IQVIA (NYSE:IQVGet Free Report) in a report released on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $285.00 price target on the medical research company’s stock. BTIG Research’s target price points to a potential upside of 30.81% from the company’s previous close.

Several other brokerages also recently issued reports on IQV. Robert W. Baird increased their price objective on shares of IQVIA from $221.00 to $226.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th. Morgan Stanley lowered their price objective on shares of IQVIA from $240.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $262.00 to $239.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, February 8th. Finally, Citigroup raised their price target on shares of IQVIA from $190.00 to $225.00 and gave the stock a “neutral” rating in a research report on Monday, December 11th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $247.21.

View Our Latest Stock Analysis on IQVIA

IQVIA Stock Down 0.1 %

Shares of NYSE:IQV opened at $217.88 on Tuesday. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 2.12. IQVIA has a 52-week low of $167.42 and a 52-week high of $234.92. The company has a 50 day moving average of $219.72 and a two-hundred day moving average of $211.12. The company has a market capitalization of $39.76 billion, a price-to-earnings ratio of 36.62, a price-to-earnings-growth ratio of 2.49 and a beta of 1.48.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Kevin C. Knightly sold 13,117 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $214.03, for a total value of $2,807,431.51. Following the sale, the insider now directly owns 7,347 shares in the company, valued at $1,572,478.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp raised its holdings in shares of IQVIA by 2.5% in the 2nd quarter. State Street Corp now owns 8,451,571 shares of the medical research company’s stock worth $1,899,660,000 after purchasing an additional 207,148 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of IQVIA by 19.1% in the 2nd quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock worth $1,335,754,000 after purchasing an additional 952,850 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of IQVIA by 2.7% in the 2nd quarter. Geode Capital Management LLC now owns 3,907,023 shares of the medical research company’s stock worth $875,861,000 after purchasing an additional 102,862 shares in the last quarter. Lazard Asset Management LLC raised its holdings in shares of IQVIA by 2.9% in the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after purchasing an additional 80,189 shares in the last quarter. Finally, Longview Partners Guernsey LTD raised its holdings in shares of IQVIA by 1.7% in the 2nd quarter. Longview Partners Guernsey LTD now owns 2,753,819 shares of the medical research company’s stock worth $618,976,000 after purchasing an additional 45,909 shares in the last quarter. 86.82% of the stock is currently owned by institutional investors.

About IQVIA

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.